Y
Yoshiyuki Ohsugi
Researcher at Chugai Pharmaceutical Co.
Publications - 124
Citations - 7877
Yoshiyuki Ohsugi is an academic researcher from Chugai Pharmaceutical Co.. The author has contributed to research in topics: Antibody & Interleukin 6. The author has an hindex of 41, co-authored 124 publications receiving 7568 citations. Previous affiliations of Yoshiyuki Ohsugi include Osaka University & Shinshu University.
Papers
More filters
Journal ArticleDOI
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tatsuya Tamura,Nobuyuki Udagawa,Naoyuki Takahashi,Chisato Miyaura,Sakae Tanaka,Y Yamada,Yasuo Koishihara,Yoshiyuki Ohsugi,K Kumaki,Tetsuya Taga +9 more
TL;DR: It is suggested that increased circulating or locally produced sIL-6R induces osteoclast formation in the presence of IL-6 mediated by a mechanism involving gp130, which may play an important physiological or pathological role in conditions associated with increased osteoclastic bone resorption.
Journal Article
Reshaping a Human Antibody to Inhibit the Interleukin 6-dependent Tumor Cell Growth
Koh Sato,Masayuki Tsuchiya,Jośe Saldanha,Yasuo Koishihara,Yoshiyuki Ohsugi,Tadamitsu Kishimoto,Mary M. Bendig +6 more
TL;DR: The reshaped human PM-1 antibody, consisting of human REI-based light chain and NEW-based heavy chain variable regions, could be efficacious in human multiple myeloma patients.
Journal ArticleDOI
Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130
Masashi Narazaki,Kiyoshi Yasukawa,Takashi Saito,Yoshiyuki Ohsugi,Hiroyasu Fukui,Yasuo Koishihara,George D. Yancopoulos,Tetsuya Taga,Tadamitsu Kishimoto +8 more
TL;DR: Results indicated that serum sgp130 could negatively regulate the IL-6 signal, implying physiologic roles of naturally produced serum s gp130 in modulating signals through gp130.
Journal ArticleDOI
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis.
Satoshi Serada,Minoru Fujimoto,Masahiko Mihara,Nobuo Koike,Yoshiyuki Ohsugi,Shintaro Nomura,Hiroto Yoshida,Teppei Nishikawa,Fumitaka Terabe,Tomoharu Ohkawara,Tsuyoshi Takahashi,Barry Ripley,Akihiro Kimura,Tadamitsu Kishimoto,Tetsuji Naka +14 more
TL;DR: Findings indicate that anti-IL-6R mAb treatment might represent a novel therapy for human MS through the inhibition of the development of MOG-peptide-specific Th17 cells and Th1 cells, which in turn leads to reduced infiltration of T cells into the CNS.
Journal ArticleDOI
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Masahiko Mihara,Keiko Kasutani,Makoto Okazaki,Akito Nakamura,Shigeto Kawai,Masamichi Sugimoto,Yoshihiro Matsumoto,Yoshiyuki Ohsugi +7 more
TL;DR: Significant lines of evidence indicate that tocilizumab is able to bind to both sIL-6R and mIL- 6R and to inhibit IL-6 binding to its receptors, leading to the blockade of the IL- 6 signaling through both sil-6r and mil-7R, but not block the signaling of other IL-7 family cytokines.